Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer

NCT03575234 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03575234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03575234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Withdrawn
Start date
July 1, 2020
Completion date
January 31, 2026
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus positive oropharyngeal squamous cell carcinoma, stage ii oral cavity squamous cell carcinoma ajcc v6 and v7, stage iii oral cavity squamous cell carcinoma ajcc v6 and v7, stage iii oropharyngeal squamous cell carcinoma ajcc v7, stage iva oral cavity squamous cell carcinoma ajcc v6 and v7